Wire · opportunities
Swedish biotech raises SEK 100 million after brain cancer breakthrough
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
Swedish biotech Oncopeptides raised SEK 100 million after reporting progress with its peptide-drug conjugate platform in treating glioblastoma, based on initial patient results from the INSULA study at Oslo University Hospital. The drug melflufen, already EMA-approved for multiple myeloma, is being tested in this new aggressive brain cancer indication.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You are looking at a new market opening in brain cancer therapeutics where melflufen's shift from multiple myeloma to glioblastoma could redefine treatment options. Your next step is to assess how your pipeline could align with peptide-drug conjugate technology for aggressive cancers.
◆ Coverage
1 source · 14 Oct 2026
◆ Related on Wire
◆ Topics